Spravato is the brand name for esketamine, which is a medication used in the treatment of depression. It was developed by Janssen Pharmaceuticals and received approval from the U.S. Food and Drug Administration (FDA) for use in adults with treatment-resistant depression (TRD). Esketamine is a form of ketamine, an anesthetic and dissociative drug, and it is administered as a nasal spray. It is used in conjunction with oral antidepressant medications. Esketamine has shown promise in providing rapid relief of depressive symptoms.
The FDA has created stringent requirements for a provider to be able to administer Spravato. In keeping with our commitment to provide our community with the most treatment options, Novus Behavioral Health has gained certification allowing us to give this innovative treatment. However, its use is typically closely monitored and administered in a healthcare setting due to potential side effects and safety concerns.
Spravato is considered a potential treatment option for individuals facing treatment-resistant depression, particularly those with severe depressive symptoms or suicidal thinking. It offers rapid relief when conventional antidepressants have proven ineffective. In cases where comorbid conditions like anxiety or PTSD compound the patient’s suffering, Spravato can be very valuable, as it can address both depressive and anxiety symptoms.
While undergoing Spravato treatment, you should expect to visit the office for two hours per visit. The medication is administered as a nasal spray, twice a week during the initial treatment phase, with the frequency decreasing in the maintenance phase. Spravato is known for its rapid onset of action, providing potential relief from depressive symptoms within hours or days. You’ll be closely monitored by healthcare professionals to ensure safety, and your treatment provider will regularly assess your progress and make adjustments as needed. It is often used alongside other treatments like oral antidepressant medications and therapy, forming a comprehensive treatment plan tailored to your specific needs. The duration of Spravato treatment may vary, depending on your individual response and progress.
Because Spravato has been FDA approved as a therapy for treatment resistent depression (TRD). Spravato costs are covered by most major health plans. Patients are responsible for the cost of their copay, coinsurance or deductible at the time of each visit. The cost of Spravato is often only around $10 with the use of their cost saving coupon.
It is a joy to see the difference this medication can make in the lives of our patients who have struggled for years with chronic depressive sympomts.